Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda Olson

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Blood|December 16, 2021
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemiaMahmoud R Gaballa, Pinaki Banerjee, Denái R Milton, et al.
Haematologica|June 4, 2026
Long-term follow-up: blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemiaJennifer Miatech, Denái R Milton, Mahmoud R Gaballa, et al.
Blood|February 2, 2018
Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletionBetül Oran, Rima M Saliba, Yudith Carmazzi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 15, 2019
Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with LymphomaNeeraj Y Saini, Rima M Saliba, Gabriela Rondon, et al.
Transplantation and Cellular Therapy|July 30, 2021
Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical TrialRohtesh S Mehta, Roland Bassett, Julianne Chen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 5, 2026
Treatment of Progressive Multifocal Leukoencephalopathy with Third-Party Allogeneic BK Virus T CellsAmanda Olson, Ye Li, David Marin, et al.
Journal of Medicinal Chemistry|May 26, 2007
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotensionGui-Dong Zhu, Viraj B Gandhi, Jianchun Gong, et al.
Blood|June 2, 2016
Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantationTakuya Sekine, David Marin, Kai Cao, et al.
Blood Advances|August 23, 2023
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbiditiesUday R Popat, Oren Pasvolsky, Roland Bassett, et al.
Transplantation and Cellular Therapy|September 19, 2021
Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation CyclophosphamideRohtesh S Mehta, Rima M Saliba, Leonard C Alsfeld, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Blood|December 16, 2021
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemiaMahmoud R Gaballa, Pinaki Banerjee, Denái R Milton, et al.
Haematologica|June 4, 2026
Long-term follow-up: blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemiaJennifer Miatech, Denái R Milton, Mahmoud R Gaballa, et al.
Blood|February 2, 2018
Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletionBetül Oran, Rima M Saliba, Yudith Carmazzi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 15, 2019
Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with LymphomaNeeraj Y Saini, Rima M Saliba, Gabriela Rondon, et al.
Transplantation and Cellular Therapy|July 30, 2021
Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical TrialRohtesh S Mehta, Roland Bassett, Julianne Chen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 5, 2026
Treatment of Progressive Multifocal Leukoencephalopathy with Third-Party Allogeneic BK Virus T CellsAmanda Olson, Ye Li, David Marin, et al.
Journal of Medicinal Chemistry|May 26, 2007
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotensionGui-Dong Zhu, Viraj B Gandhi, Jianchun Gong, et al.
Blood|June 2, 2016
Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantationTakuya Sekine, David Marin, Kai Cao, et al.
Blood Advances|August 23, 2023
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbiditiesUday R Popat, Oren Pasvolsky, Roland Bassett, et al.
Transplantation and Cellular Therapy|September 19, 2021
Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation CyclophosphamideRohtesh S Mehta, Rima M Saliba, Leonard C Alsfeld, et al.
Pageof 8